What is the best strategy for treating TB-HIV co-infected patients with HAART and rifampicin without saquinavir? [4]

International Journal of Tuberculosis and Lung Disease

Volumn 11, Issue 8, 2007, Pages 933-934

  Torres, Thiago S ^a   Rolla, Valéria C ^a  

^a Funda??o Oswaldo Cruz   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RITONAVIR; SAQUINAVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; MEDICAL DECISION MAKING; PRACTICE GUIDELINE; PRIORITY JOURNAL; SUPERINFECTION; TUBERCULOSIS; COINFECTION; HIV INFECTIONS;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COINFECTION; HIV INFECTIONS; HUMANS; RIFAMPIN; SAQUINAVIR; TUBERCULOSIS;

EID: 34547732850     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (4)

1. Torres T S, Rolla V C. Saquinavir and rifampicin for tuberculosis and AIDS: new considerations. Int J Tuberc Lung Dis 2006; 10: 1299-1301.
2. Ribera E, Azuaje C, Lopes R M, et al. Once daily regimen of saquinavir, ritonavir, didanosine and lamivudine in HIV infected patients with standard tuberculosis therapy. J Acquir Immune Defic Syndr 2005; 40: 317-323.
3. Rolla V C, Vieira M A S, Ferreira Filho M, et al. Safety, efficacy and pharmacokinetics of ritonavir 400 mg/saquinavir 400 mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006; 26: 469-479.
4. La Porte C J L, Colbers E P H, Bertz R, et al. Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampicin in healthy volunteers. Antimicrob Agents Chemother 2004; 48: 1553-1560.